• TOP
  • News
  • News release
  • FIMECS, Inc. Enters a New Research Collaboration with National Institute of Genetics


FIMECS, Inc. Enters a New Research Collaboration with National Institute of Genetics

News release Download PDF

Kanagawa, Japan – FIMECS, Inc. (“FIMECS”), a private biotechnology company creating a new class of drugs based on protein degradation, today announced the launch of a new research ollaboration
with National Institute of Genetics in Shizuoka, Japan

The new collaboration is with the research group of professor Masato Kanemaki of Division of Molecular Cell Engineering at National Institute of Genetics, an expert in Molecular Biology, Genetics/Chromosome dynamics, and Cellular biology. The research collaboration activities will focus on developing novel target validation technology for protein degradation drug discovery by utilizing in vivo auxin-inducible degron (AID) technology 1).

Yusuke Tominari, Chief Executive Officer and Chief Scientific Officer, said: “We are delighted to collaborate with professor Kanemaki and his group. Applying their extensive experience and knowledge of auxin-inducible degron technology into drug discovery process will create the strong basis to predict the effect of target protein degradation. Combined with our original platform of degrader discovery “RaPPIDS™”, we can accelerate to generate innovative drugs for undruggable proteins. We look forward to a productive relationship.”

Prof. Kanemaki, National Institute of Genetics, added: “We are excited to collaborate with FIMECS to progress the drug discovery value chain with target protein degradation by utilizing our knowledge of auxin-inducible degron technology.”

About FIMECS, Inc.
FIMECS, Inc. is developing a new class of targeted protein degradation therapeutics for the treatment of ‘undruggable’ cancer targets. By integrating proprietary E3 ligase binder with olecule-designing capability, the company is developing proprietary therapeutic programs to rapidly induce the degradation of targeted proteins along with “RaPPIDS™” platform. Utilizing our drug iscovery platform to internal and collaboration projects, the company seeks to provide life-saving medicine to patients all over the world.

# # #

FIMECS, Inc. Media and Investor Contact:
Yusuke Kohno, CFO and VP of corporate development
TEL: +81-50-5328-9458

1) AID technology: The technology enables to lead rapid and inducible degradation of AID-tagged target proteins in mammalian cells by the addition of plant hormone auxin to culture medium.

Back to news list

Return to TOP